Genmab/AbbVie Partnered Blood Cancer Combination Drug Cuts Risk Of Disease Progression By 79%
1. Genmab's trial for epcoritamab shows significant efficacy in R/R follicular lymphoma. 2. Epcoritamab's partnership with AbbVie correlates with positive trial outcomes. 3. FDA has accepted priority review for epcoritamab regimen with a 2025 deadline. 4. Genmab raised 2025 sales guidance, indicating strong market performance. 5. Epcoritamab may provide compelling treatment options if approved.